GRFS · Grifols, S.A.

Summary

Grifols, S.A. reports that its Board of Directors has decided to initiate a process to evaluate a potential Initial Public Offering in the United States of a portion of the shares of its subsidiary, parent of its U.S. Biopharma business, as part of self-sufficiency programs. The transaction is subject to regulatory and legal requirements, internal approvals, and market conditions, with no assurance of completion.

Key takeaways

• Board of Directors initiated process to evaluate potential U.S. IPO
• IPO targets portion of shares of subsidiary (parent of U.S. Biopharma business)
• Driven by self-sufficiency programs for Biopharma businesses
• Subject to regulatory/legal requirements, internal approvals, market conditions
• No assurance IPO will be undertaken or completed
• Grifols continues trading in Spain via mercado continuo